The Globe and Mail reports in its Friday, April 26, edition that Desjardins Securities analyst Gary Ho has an unchanged "buy" recommendation on CareX. The Globe's David Leeder writes in the Eye On Equities column that Mr. Ho gave his share target a 25-cent boost to $3.75. Analysts on average target the shares at $3.91. Mr. Ho says in a note: "We are constructive heading into Q1, with stable bed count and consistent progress on EBITDA margin expansion. Potential upside includes the benefits from the new McKesson procurement contract, efficiencies from the hub-and-spoke model and RFP opportunities in the pipeline. We upped our 2H24 and 2025 EBITDA margin estimates; management remains confident in its 10-per-cent target exiting 2024." The Globe reported on Aug. 17, 2022, that Mr. Ho had reaffirmed his "buy" recommendation for CareRx. The shares could then be had for $3.75.